Intended for asthma to manage airway inflammation and support respiratory stability.
Mechanism of Action
The active substance binds to glucocorticoid receptors in the airways. This inhibits the release of inflammatory mediators and suppresses the migration of inflammatory cells, leading to decreased airway swelling and improved breathing function.
Route of Administration
Inhalation
Onset Time
1–2 weeks
Duration
12–24 hours
Contraindications
Status asthmaticus, Hypersensitivity to budesonide
Severe Adverse Events
Adrenal suppression, Paradoxical bronchospasm, Anaphylaxis — requires immediate medical attention
Common Side Effects
Hoarseness, Cough, Throat irritation
Uncommon Side Effects
Oral candidiasis, Nasopharyngitis, Headache
Drug Interactions
Alcohol, Ketoconazole, Ritonavir, Clarithromycin
Pregnancy Safety Warnings
FDA Category B: No evidence of fetal risk. Breastfeeding: Excreted in milk; compatible with caution.
Age Restrictions
Safety and efficacy established in pediatric patients six months and older.
Information related to Budecort is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
